Showing 106 of 106on this page. Filters & sort apply to loaded results; URL updates for sharing.106 of 106 on this page
UBX1325 | CAS#:2271269-01-1 | Chemsrc
A Look At Unity's UBX1325 Phase 1 Results (NASDAQ:UBX) | Seeking Alpha
UBX1325 | TargetMol
New data on anti-aging therapy: UBX1325 targets to eliminate senescent ...
Data from Phase 2 BEHOLD study of UBX1325 in DME patients-Unity ...
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema ...
UNITY Biotechnology (UBX) Shows Promise with Senolytic UBX1325 i
CASE STUDY. UBX1325 MoA in Age-related Macular Degeneration for Unity ...
UBX1325 DME Phase 2b Study: 36-Week Results & Corporate Updates
New Data for Phase 2 Study of UBX1325 - Eyetube
Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still ...
VIDEO: UBX1325 in wet AMD does not meet noninferiority endpoint despite ...
Slide 5
$亚盛医药-B(06855)$ Unity刚刚公布了引进的亚盛UBX1325的DME二期数据(24周数据,8月份公布是1... - 雪球
2023年3月 | 失败临床研究TOP10医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Slide 3
Slide 25
Slide 24
Slide 6
米UNITY Biotechnology社のBCL-xL阻害剤UBX1325のPhase I試験の結果がNature medicineの論文に ...
Slide 10
Slide 11
Slide 12
Slide 7
Slide 9
Slide 13
Slide 22
Slide 15
Slide 27
Senolytic therapy: ‘Entirely new paradigm’
$亚盛医药-B(06855)$ UNITY 刚发了新闻稿,将在2月14日召开投资者会议,公布管线UBX1325治疗 AM... - 雪球
Slide 4
Slide 17
Slide 20
在研品种 - 亚盛医药
UNITY Biotechnology Program Update on ENVISION, the Phase 2 Clinical ...
Unity Biotechnology社の老化細胞除去薬UBX1325のPh-II試験。1回投与で視力回復が48週間継続の結果 /Amrit ...
Bcl-xL抑制剂II期研究未达主要终点,UNITY股价大跌46%医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
UBX | UNITY Biotechnology Announces Results from Phase 2 ENVISION Study ...
Slide 21
The UBX domain in UBXD1 organizes ubiquitin binding at the C-terminus ...
Slide 30
亚盛的第一个海外BD,看到了成药的希望。 $亚盛医药-B(06855)$亚盛的第一个海外BD,有了成药的希望。2016年授权给美国 UNITY ...
The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and ...
Discovery of A-1331852, a First-in-Class, Potent, and Orally ...
Baseline BCL-xL expression and inhibition of BCL-xL with ABT-263 ...
The Role of Bcl-xL Protein in Viral Infections - PMC
Multiple UBXN family members inhibit retrovirus and lentivirus ...
BCL-XL–targeting antibody-drug conjugates are active in preclinical ...
Genetic and pharmacological regulation of UBXN2A suppress colon cancer ...
Oncology Reports
Computational design of BclxL inhibitors that target transmembrane ...
RCSB PDB - 9IGB: Structure of human Bcl-xL in complex with small ...
Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in ...
Combined inhibition of aurora kinases and Bcl-xL induces apoptosis ...
Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13 ...
The UBXN1 Protein Associates with Autoubiquitinated Forms of the BRCA1 ...
Alternative splicing of BCL-x is controlled by RBM25 binding to a G ...
A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor - PMC
The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is ...
Current Advances and Future Strategies for BCL-2 Inhibitors: Potent ...
Blockade of the STAT3/BCL-xL Axis Leads to the Cytotoxic and Cisplatin ...
A-1293102 | BCL-XL Inhibitor | MedChemExpress
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer ...
AbbVie's Surzetoclax: A Next-Gen BCL-2 Inhibitor for Hematologic ...
The crystal structure of the Bcl-xL/HBx-aa113–135 complex. a Cartoon ...
Bcl-xL Affects Group A Streptococcus-Induced Autophagy Directly, by ...
Redefining Cancer Therapy: Toward BCL-XL/BCL-2 Dual Inhibitors with ...
Frontiers | Potentiating doxorubicin activity through BCL-2 inhibition ...
Doxorubicin selectively induces apoptosis through the inhibition of a ...
A combination of Bcl-xL- specific inhibitor A-1155463 and DNA-damaging ...
Bcl-xL Is Spontaneously Inserted into Preassembled Nanodiscs and ...
Protein Levels of Anti-Apoptotic Mcl-1 and the Deubiquitinase USP9x Are ...
WO2023288100A1 - Liposomal formulations of bcl inhibitors - Google Patents
Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer ...
RCSB PDB - 9AQZ: Crystal structure of Bcl-xL in complex with a small ...
停药一个月,皮肤逆龄11岁?Rubedo首个局部清除衰老细胞药:不仅安全,表观年龄还倒拨了! - 知乎
老化細胞除去薬はいつ実用化する?日本の治験・承認状況とセノリティクスの効果【2026年】 | DailyDrops Info
Invitrogen Bcl-X Monoclonal Antibody (2H12), eBioscience 50 μg ...